Project Grant R01CA300362
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $635K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
- Federal Project Grant Award Summary The University of Utah received a $154,000 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2027. This technology-oriented project will develop and validate a novel genetic mouse model system for pancreatic ductal adenocarcinoma (PDAC) research. The primary deliverable is the creation and functional validation of a "FLP-OUT" mouse model using a...
- Federal Grant Award Summary The University of Utah's Office of Sponsored Projects received a $183,600 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, through August 31, 2028. This award supports research investigating the combination of JAK (Janus kinase) inhibitors with immune checkpoint inhibitors to overcome resistance to checkpoint blockade immunotherapy in cancer patients, particularly those with relapsed...
- Federal Grant Award Summary The National Cancer Institute awarded a $669,949 Project Grant (CFDA 93.396, Cancer Biology Research program) to the University of Utah, effective August 15, 2025, through July 31, 2030, to elucidate the functional role and therapeutic potential of G Protein-Coupled Receptor Kinase 2 (GRK2) in primary and therapy-resistant basal cell carcinoma (BCC). The research addresses a critical therapeutic gap in BCC treatment, where existing Smoothened (SMO) inhibitors lose...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $510,431 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2025 through June 30, 2030. This award supports fundamental research investigating the mechanisms of metastatic recurrence and therapeutic resistance in melanoma, with particular emphasis on understanding how aging influences tumor dormancy and the microenvironment. The research examines Wnt signaling...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $661,721 Project Grant to the University of California, San Diego, with an award date of April 1, 2026, and a completion date of March 31, 2031. This five-year research initiative focuses on systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The project will utilize novel high-throughput...
- Federal Grant Award Summary The National Cancer Institute awarded $2.82 million to the Regents of the University of Michigan under the Cancer Treatment Research program (CFDA 93.395) on August 6, 2025, with completion targeted for July 31, 2029. This Project Grant supports the development of new methods to measure metabolic pathway activity in glioblastomas (GBMs), deadly brain cancers that rewire their metabolism to enable growth, invasion, and treatment resistance. The research deliverables...
- Federal Project Grant Summary Colorado State University received a $629,341 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 12, 2025, with an ultimate completion date of August 31, 2030. The research project focuses on developing improved cancer treatment methods through investigation of Focal Adhesion Kinase (FAK) inhibition as a dual-targeting strategy for osteosarcoma, the most common primary malignant...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $135,993 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2025, with completion anticipated by May 31, 2027. The award funds investigative research examining the role of the Abelson (ABL) kinase-regulated hypoxia inducible factor-1 alpha (HIF-1A) and transcriptional co-activator with PDZ-binding motif (TAZ) signaling...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Miami's Office of Research Administration within the School of Medicine a Project Grant totaling $109,076.00 under the Cancer Research Manpower program (CFDA 93.398) on December 17, 2025. The award supports biomedical research training and career development initiatives focused on cancer research through September 1, 2029. This project grant funds the institution's capacity to provide integrated...